Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Gordon Brent Mills

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0144-9614; OpenAlex author ID A5005221518, A5129560433; NIH RePORTER profile ID 1877572. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
2
Collaborators
72
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 grant · 2022: 1 paper · 2023: none · 2024: 4 papers · 2025: 3 papers · 2026: 1 paper

Papers 15

  1. IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-25-1612↗
  2. Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients. Co-author DOI 10.1038/s41467-025-62685-y↗
  3. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  4. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  5. Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2024.101115↗
  6. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Co-author DOI 10.1080/14796694.2024.2395235↗
  7. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Co-author DOI 10.1080/15384047.2024.2421584↗
  8. Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer. Co-author DOI 10.3390/cancers16213650↗
  9. Mechanical Stress Signaling in Pancreatic Cancer Cells Triggers p38 MAPK- and JNK-Dependent Cytoskeleton Remodeling and Promotes Cell Migration via Rac1/cdc42/… Co-author DOI 10.1158/1541-7786.mcr-21-0266↗
  10. The roles of MAGEA6 variants in pancreatic cancer development and their potential impact on cancer immunotherapy. First author DOI 10.1080/15548627.2020.1802091↗
  11. Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. Co-author DOI 10.7554/elife.48963↗
  12. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  13. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2016.07.023↗
  14. Functional annotation of rare gene aberration drivers of pancreatic cancer. Co-author DOI 10.1038/ncomms10500↗
  15. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-14-1854↗

Grants 1

  1. Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer U01CA217842↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 6 shared papers, 2024–2026 · strength 1.09
  2. Charles D. Lopez · 5 shared papers, 2024–2026 · strength 0.86
  3. Jonathan Robert Brody · 4 shared papers, 2024–2025 · strength 0.65
  4. Adel Kardosh · 4 shared papers, 2024–2025 · strength 0.64
  5. Lisa M. Coussens · 3 shared papers, 2025–2026 · strength 0.54
  6. Brett C. Sheppard · 3 shared papers, 2024–2025 · strength 0.48
  7. Benjamin Deneen · 1 shared grant, 2021 · strength 0.44
  8. Kenneth L. Scott · 1 shared grant, 2021 · strength 0.44
  9. Katie E. Blise · 2 shared papers, 2025–2026 · strength 0.38
  10. Yiu Huen Tsang · 3 shared papers, 2016–2020 · strength 0.38
  11. Terry K. Morgan · 2 shared papers, 2025 · strength 0.37
  12. Patrick Joseph Worth · 2 shared papers, 2025 · strength 0.31
  13. Isabel A. English · 2 shared papers, 2025 · strength 0.31
  14. Jason M. Link · 2 shared papers, 2025 · strength 0.31
  15. Motoyuki Tsuda · 2 shared papers, 2025 · strength 0.31
  16. Alexander Savio Ramos Guimaraes · 2 shared papers, 2024–2025 · strength 0.31
  17. Kyle P. Gribbin · 1 shared paper, 2026 · strength 0.23
  18. Zheng Xia · 1 shared paper, 2026 · strength 0.23
  19. Canping Chen · 1 shared paper, 2026 · strength 0.23
  20. Mara H. Sherman · 1 shared paper, 2026 · strength 0.23
  21. Katelyn T. Byrne · 1 shared paper, 2026 · strength 0.23
  22. Aaron J. Grossberg · 1 shared paper, 2025 · strength 0.21
  23. Thuy T. M. Ngo · 1 shared paper, 2025 · strength 0.21
  24. Paul T. Spellman · 1 shared paper, 2025 · strength 0.21
  25. Travis W. Moore · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.